| scholarly article | Q13442814 |
| P2093 | author name string | Min Wu | |
| Katherine Tyner | |||
| Wenlei Jiang | |||
| Dajun Sun | |||
| Rodney Rouse | |||
| P2860 | cites work | Sodium ferric gluconate (SFG) in complex with sucrose for IV infusion: bioequivalence of a new generic product with the branded product in healthy volunteers. | Q51371408 |
| The nanoparticle–protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century | Q55167511 | ||
| The effects of aggregation and protein corona on the cellular internalization of iron oxide nanoparticles | Q57355675 | ||
| Protein source and choice of anticoagulant decisively affect nanoparticle protein corona and cellular uptake | Q57947041 | ||
| An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin | Q73566013 | ||
| Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis | Q79814593 | ||
| Structure, chemistry, and pharmacokinetics of intravenous iron agents | Q81110731 | ||
| Acute oxidative stress following intravenous iron injection in patients on chronic hemodialysis: a comparison of iron-sucrose and iron-dextran | Q83086072 | ||
| Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America | Q84557744 | ||
| A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity | Q85160576 | ||
| On the relative safety of parenteral iron formulations | Q28262418 | ||
| A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications | Q28307966 | ||
| Evaluating the effect of assay preparation on the uptake of gold nanoparticles by RAW264.7 cells | Q28383420 | ||
| Macrophage silica nanoparticle response is phenotypically dependent | Q28392242 | ||
| Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status | Q28648176 | ||
| FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia | Q34041146 | ||
| Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran | Q34609688 | ||
| A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients | Q34885195 | ||
| The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles | Q35583445 | ||
| Labile iron: manifestations and clinical implications | Q35976907 | ||
| A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. | Q36722337 | ||
| Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis | Q37290642 | ||
| A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED) | Q37368915 | ||
| Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? | Q37656315 | ||
| Ferric carboxymaltose: a review of its use in iron deficiency | Q38271890 | ||
| Labile iron in parenteral iron formulations: a quantitative and comparative study | Q38344983 | ||
| Protein Corona Influences Cellular Uptake of Gold Nanoparticles by Phagocytic and Nonphagocytic Cells in a Size-Dependent Manner | Q38835760 | ||
| Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD. | Q39317065 | ||
| Degradation of superparamagnetic iron oxide nanoparticle-induced ferritin by lysosomal cathepsins and related immune response | Q39364948 | ||
| Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line | Q39587370 | ||
| Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients | Q40523271 | ||
| Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products | Q40731001 | ||
| Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? | Q42276525 | ||
| Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells | Q42464960 | ||
| Evolution of iv iron compounds over the last century | Q43248002 | ||
| Transferrin saturation with intravenous irons: an in vitro study | Q45028937 | ||
| Suspected iron dextran-related adverse drug events in hemodialysis patients | Q46183426 | ||
| Significance of cell "observer" and protein source in nanobiosciences | Q46195168 | ||
| Update on adverse drug events associated with parenteral iron | Q46212164 | ||
| Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels | Q46546922 | ||
| Use of parenteral iron products and serious anaphylactic-type reactions | Q46599031 | ||
| Superparamagnetic iron oxide nanoparticle uptake alters M2 macrophage phenotype, iron metabolism, migration and invasion | Q46614943 | ||
| Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats | Q47892746 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Nanomaterials | Q27724944 |
| P1476 | title | Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake | |
| P478 | volume | 7 |
| Q47892746 | Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats |
| Q47198705 | Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization. |
| Q91069626 | Innovation for Generic Drugs: Science and Research Under the Generic Drug User Fee Amendments of 2012 |
Search more.